Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Pancreatic Cancer

 

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01839487

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)
A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer

Investigator: Andrew Coveler, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01360853

LY2157299 for Metastatic Cancer and Advanced or Metastatic Pancreatic Cancer
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Investigator: Andrew Coveler, MD;   Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01373164

FOLFIRINOX w/wo Hyperacute®-Pancreas Immunotherapy for Pancreatic Cancer (8028)
A Phase III Study Of FOLFIRINOX With Or Without Hyperacute®-Pancreas (algenpantucel-L) Immunotherapy In Subjects With Borderline Resectable Or Locally Advanced Unresectable Pancreatic Cancer

Investigator: Andrew Coveler, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01836432

Temozolomide and Pazopanib Hydrochloride for Pancreatic Cancer
A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01465659

PRI-724 Plus Gemcitabine for Advanced or Metastatic Pancreatic Adenocarcinoma (20141153)
Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ B-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy after Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)

Investigator: Elena Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01764477

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Veliparib for Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors

Investigator: Elizabeth Swisher, MD;   Conditions: High Grade Serous Ovarian Cancer, BRCA Mutated Breast Cancer;    Status: Closed;   Study ID: NCT01853306